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Results. The dose administered was from 69.9 to 75.9Gy (average 74.2Gy), 5 days a week, in a fractionation of 2.3Gy per day (97%),
with 7 ﬁelds (97%) shaped three-dimensionally and photons of 18MV. The tolerance was excellent, showing no gastrointestinal
toxicity in 88.5%, G1 in 11.5%. Genitourinary toxicity was G0 in 55%, G1 in 40%, G2 in 5%.
Conclusion. The hypofractionated treatment is safe, showing minimal acute toxicity. Subsequently we will assess the long-term
toxicity, monitoring clinical and analytically through PSA control.
http://dx.doi.org/10.1016/j.rpor.2013.03.471
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Introduction. Despite recommendations in international guidelines, speciﬁc treatment depends on additional prognostic, clinical,
and personal factors. Relevant issues in the personalized treatment of high-risk prostate cancer (HRPC) include dose escalation,
treatment volumes, androgen deprivation therapy (ADT) strategy, and expected beneﬁts.
Objectives. To assess the recommendations of radiation oncologists in controversial areas of HRPC treatment.
Methods. The ÁGORA project involved 18 radiation oncologists and comprised 4 phases: (1) identiﬁcation of controversial areas
in the treatment of HRPC with aLHRH; (2) selection of speciﬁc literature; (3) preparation of case reports and questionnaires in 4
settings; (4) discussion of the case reports at regional meetings (May–July 2011). Therapeutic procedures were classiﬁed as “highly
recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion of the responses was
considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In young sexually active patients with HRPC (1 risk factor) and low IPSS, the most widely accepted treatment was neoadju-
vantHT (2–3months+ concomitant RT+adjuvantHT 24months) (SEM0.14). In young sexually active patientswithmoderate IPSS,
the consensus reached (SEM 0) was neoadjuvant HT 2–3 months+RT+adjuvant HT 24 months. In older, sexually inactive patients
with high IPSS, consensus was reached (SEM 0) on offering neoadjuvant HT 2–3 months+ concomitant treatment+adjuvant HT
24 months. In elderly patients with HRPC (1 risk factor) and a moderate post-TUR IPSS, the most accepted treatment (SEM 0.25)
was neoadjuvant HT 3 months+ concomitant ADT/RT.
Conclusions. Given the life expectancy of patients with HRPC, radiation oncologists agree that the ﬁrst option to be offered is
the combination of long-term HT combined with external RT. Treatment decisions in this group depend mainly on age and
unfavorable prognostic factors.
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Introduction. Both the CAPORT and AEU studies report a high prevalence of intermediate-risk prostate cancer (IRPC). Despite
recommendations in international guidelines, speciﬁc treatment depends on various prognostic, clinical, and personal factors.
Objectives. To assess radiation oncologists recommendations in controversial scenarios in IRPC and its treatment.
Methods. The ÁGORA project involved 18 radiation oncologists and comprised 4 phases: (1) identiﬁcation of controversial areas
in the treatment of IRPC with antigen deprivation (AD); (2) selection of speciﬁc literature; (3) preparation of case reports and
questionnaires in 4 settings; (4) discussion of the case reports at regional meetings (May–July 2011). Therapeutic procedures were
classiﬁed as “highly recommendable”, “recommendable in some cases”, or “not recommendable/not applicable”. The dispersion
of the responses was considered to indicate consensus (SD<0.15) or high variability (SD>0.85).
Results. In young sexually active patients with IRPC (1 factor) and low IPSS, the strongest agreement was for treatment consid-
ered inappropriate: Active monitoring and the combination of radiotherapy and bicalutamide 150mg/d. A broad consensus was
reached for radiotherapy combined with short-term AD and for brachytherapy. Consensus was weaker with respect to radical
prostatectomy and radiotherapy alone. In young sexually active patients with IRPC (>1 factor) and moderate IPSS, external radio-
therapy and short-term AD (4–6 months) was highly recommended. In older sexually inactive IRPC with a high IPSS, consensus
was reached on neoadjuvant AD 3 months+ concomitant radiotherapy. Brachytherapy alone should not be offered. No consensus
